转化医学杂志

参考文献

[1]Veronesi U,Cascinellin,Marianin L,et al.Twenty-yearfollow up of a randomized study comparing breast-con-serving surgery with radical mastectomy for early breastcancer[J].N Engl J Med,2002,347(16):1227-1232.

[2]Fisher B,Anderson S,Bryant J,et al.Twenty-year fol-low-up of a randomized trail comparing total mastecto-my,lumpectomy,and lumpectomy plus irradiation forthe treatment of invasive breast cancer[J].N Engl JMed,2002,347(16):1223-1241.

[3]van Dongen JA,Voogd AC,Fentiman IS,et al.Long-term results of a randomized trail comparing breast-conserving therapy with mastectomy:European Organ-ization for Research and Treatment of Cancer 10801trial[J].J Natl Cancer Inst,2000,92(14):1143-1150.

[4]Veronesi U,Paganelli G,Viale G,et al.A randomizedcomparison of sentinel-node biopsy with routine axilla-ry dissection in breast cancer[J].N Engl J Med,2003,349(6):546-553.

[5]Prosnitz LR,Marks LB.Partial breast irradiation:acautionary note[J].Int J Radiat Oncol Biol Phys,2006,65(2):319-321.

[6]Goyal A,Mansel RE.Recent advances in sentinellymph node biopsy for breast cancer[J].Curr Opin On-col,2008,20(6):621-626.

[7]Huang EH,Tucker SL,Strom EA,et al.Postmastecto-my radiation improves local regional control and sur-vival for selected patients with locally advanced breastcancer treated with neoadjuvant chemotherapy andmastectomy[J].J Clin Oncol,2004,22(23):4691-4699.

[8]韩肖燕,陈悦,侯敏敏,等.上皮性卵巢癌AIB1蛋白表达水平及与雌、孕激素受体表达的相关性研究[J].实用肿瘤杂志,2009,24(4):341-344.

[9]周道平,王彬,邢晓皖.Ki-67、p53蛋白在乳腺癌组织的表达及临床意义[J].实用肿瘤杂志,2009,24(2):136-139.

[10]杨顺娥,李迅.雌激素受体β和人类表皮生长因子受体2在乳腺癌中的表达及其临床意义[J].中华肿瘤杂志,2007,29(10):767-768.

[11]Vogel CL,Cobleigh MA,Tripathy D,et al.First lineherceptin monotherapy in metastatic breast cancer[J].Oncology,2001,61 Suppl 2:37-42.

[12]Arpino G,Wiechmann L,Osborne CK,et al.Crosstalkbetween the estrogen receptor and the HER tyrosinekinase receptor family:molecular mechanism and clini-cal implications for endocrine therapy resistance[J].Endocr Rev,2008,29(2):217-233.

[13]Bonadonna G,Moliterni A,Zambetti M,et al.30 years'follow up of randomised studies of adjuvant CMF inoperable breast cancer:cohort study[J].BMJ,2005,330(7485):217.

[14]江泽飞.乳腺癌“围手术期”治疗若干热点问题——《中国版NCCN乳腺癌临床实践指南》解读[J].中华医学杂志,2008,88(8):508-510.

[15]Goldhirsch A,Wood WC,Gelber RD,et al.Progressand promise:highlights of the international expert con-sensus on the primary therapy of early breast cancer2007[J].Ann Oncol,2007,18(7):1133-1144.

[16]Slamon DJ,Leyland-Jones B,Shak S,et al.Use ofchemotherapy plus a monoclonal antibody againstHER2 for metastatic breast cancer that overexpressesHER2[J].N Engl J Med,2001,344(11):783-792.

[17]王涛,江泽飞,宋三泰.分子靶向性药物赫赛汀治疗乳腺癌临床应用新进展[J].国外医学:肿瘤学分册,2003,30(2):139-142.

[18]张少华,宋三泰.乳腺癌分子靶向治疗进展[J].实用肿瘤杂志,2008,23(6):495-497.

[19]Miller KD,Chap LI,Holmes FA,et al.Randomized phaseⅢtrial of capecitabine compared with bevacizumab pluscapecitabine in patients with previously treated metastaticbreast cancer[J].J Clin Oncol,2005,23(4):792-799.

[20]Kadowaki N,Ho S,Antonenko S,et al.Subsets of hu-man dendritic cell precursors express different toll-likereceptors and respond to different microbial antigens[J].J Exp Med,2001,194(6):863-869.

[21]Jarrossay D,Napolitani G,Colonna M,et al.Specializa-tion and complementarity in microbial molecule recog-nition by human myeloid and plasmacytoid dendriticcells[J].Eur J Immunol,2001,31(11):3388-3393.

[22]Assier E,Marin-Esteban V,Haziot A,et al.TLR7/8 ago-nists impair monocyte-derived dendritic cell differentiationand maturation[J].J Leukoc Biol,2007,81(1):221-228.